Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Sol-Gel TechnologiesFRA:4SG 52 EBITDA Margin % is -704.29% as of Jun. 2026. GuruFocus rates FRA:4SG with a GF Score™ of 52/100 and a GF Value™ of €4.63 (Significantly Overvalued). The stock has 3 warning signs investors should review. Among 940 Biotechnology companies, Sol-Gel Technologies ranks worse than 79.47% on this metric.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Sol-Gel Technologies EBITDA Margin % Related Terms
Sol-Gel Technologies EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Sol-Gel Technologies's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:4SG vs SABS, BCYC, CYDY: EBITDA Margin % Comparison
For the Biotechnology subindustry, Sol-Gel Technologies's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sol-Gel Technologies EBITDA Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Sol-Gel Technologies's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Sol-Gel Technologies's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sol-Gel Technologies (FRA:4SG) has a EBITDA Margin % of -704.29% as of Jun. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Sol-Gel Technologies and its competitors. According to the industry distribution chart, Sol-Gel Technologies ranks #747 out of 940 companies in the Biotechnology industry, placing it in the top 79.5%.
Is Sol-Gel Technologies' EBITDA Margin % too high?
Sol-Gel Technologies' current EBITDA Margin % is -704.29%. Based on the distribution chart, Sol-Gel Technologies ranks #747 out of 940 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Sol-Gel Technologies has a GF Score™ of 52/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Sol-Gel Technologies' EBITDA Margin % compare to SABS and BCYC?
According to the Biotechnology industry distribution chart, Sol-Gel Technologies ranks #747 out of 940 companies for EBITDA Margin %. This places Sol-Gel Technologies in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Sol-Gel Technologies and its competitors. Sol-Gel Technologies's current EBITDA Margin % is -704.29%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sol-Gel Technologies stock overvalued right now?
Based on GuruFocus' analysis, Sol-Gel Technologies (FRA:4SG) is currently considered Significantly Overvalued. The stock's GF Value™ is €4.63, compared to a current price of €63.50 — trading 1271.5% above its estimated fair value. The current EBITDA Margin % is -704.29%. Sol-Gel Technologies' overall GF Score™ is 52/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Sol-Gel Technologies (FRA:4SG), the current EBITDA Margin % is -704.29% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sol-Gel Technologies (FRA:4SG) Overvalued in 2026?
Based on GuruFocus' analysis, Sol-Gel Technologies stock appears to be overvalued.
The current stock price of €63.50 is trading 1271.5% above its estimated GF Value™ of €4.63.
GuruFocus considers Sol-Gel Technologies to be Significantly Overvalued.
Key valuation signals for FRA:4SG:
EBITDA Margin %: -704.29%
GF Value™: €4.63 vs. price of €63.50 (1271.5% above fair value)
No single metric tells the full story. See the FRA:4SG stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sol-Gel Technologies Ltd is a dermatology company. It is engaged in identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. The company's product candidate pipeline includes SGT-610 (Patidegib Gel 2%), a new chemical entity hedgehog signaling pathway blocker, for the chronic use and prevention of new BCC in Gorlin syndrome patients, and the topical drug candidate SGT-210 for the treatment of Darier Disease and other rare keratosis-related indications such as PC, PPK and Olmsted. It generates the majority of its revenue from the United States.
52GF Score
Get the complete analysis for FRA:4SG
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:4SG has been successfully added to your 
